Pretargeted molecular imaging and radioimmunotherapy

Area of Science:

• Oncology
• Radiochemistry
• Immunology

Background:

• Pretargeting is a multi-step approach for targeted delivery of radiolabeled agents.
• It involves an unlabeled bispecific antibody (bsMAb) localizing to the tumor, followed by a radiolabeled compound that binds to the bsMAb.
• This strategy aims to enhance tumor targeting and reduce off-target radiation exposure.

Purpose of the Study:

• To review the anti-hapten bispecific antibody (bsMAb) platform for pretargeting applications.
• To highlight its flexibility in targeting various radionuclides for imaging and therapy.
• To discuss the advantages of pretargeting in achieving high tumor-to-nontumor ratios.

Main Methods:

• Utilizing unlabeled bispecific antibodies (bsMAb) with anti-tumor binding sites.
• Administering small, fast-clearing radiolabeled compounds that bind to the bsMAb.
• Employing haptens, biotin, or oligonucleotides as linking molecules for radiolabeling.

Main Results:

• Achieving excellent tumor/nontumor ratios in less than 1 hour.
• Demonstrating rapid clearance of the radiolabeled compound, reducing systemic radiation dose.
• Showcasing the versatility of the anti-hapten bsMAb platform for diverse radionuclides.

Conclusions:

• The anti-hapten bsMAb pretargeting platform offers a flexible and effective strategy for radionuclide delivery.
• This approach significantly improves tumor targeting for both diagnostic imaging (SPECT, PET) and therapeutic applications.
• Pretargeting enhances safety and efficacy by optimizing the biodistribution of radiopharmaceuticals.